Increased dose of Jeuveau corrects glabellar lines up to 6 months

Key takeaways:

• New phase 2 results showed 40 units of Jeuveau sustained improvements in glabellar lines up to 6 months.
• Adverse events were similar to 20-unit dosages of Jeuveau and Botox.

CHICAGO — A 40-unit formulation of Jeuveau achieved positive outcomes for the treatment of glabellar lines in adults for up to 6 months, Evolus announced in a press release.

Jeuveau (prabotulinumtoxinA-xvfs, Evolus) is FDA approved at a dosage of 20 units to temporarily improve moderate to severe frown lines between the eyebrows, also called glabellar lines, in adults aged younger than 65 years. According to the company’s website, the positive effects of Jeuveau at 20 units lasts up to 4 months.

At the 2023 American Society for Dermatologic Surgery Annual Meeting, Evolus announced new phase 2 results supporting a 40-unit formulation of Jeuveau for glabellar lines that sustains improvement for up to 6 months, or 26 weeks.

“We are pleased to report the results of the completed phase 2 trial, which provides important insights about the role of this formulation in achieving longer-lasting results,” Rui Avelar, MD, chief medical officer and head of research and development, Evolus, said in the release. “This data contributes to the body of knowledge regarding the role of increasing dose and the impact on extended duration and will be of interest to health care providers and patients.”

In the multicenter, double-blind, randomized trial, 150 patients were assigned to 40 units of Jeuveau or one of two control groups — 20 units of Jeuveau or 20 units of Botox (onabotulinumtoxinA, Allergan). These patients were followed until they lost their correction or for up to 12 months.

Results showed that the 40-unit formulation of Jeuveau sustained improvements in glabellar lines, according to the validated 4-point Glabellar Line Scale.

Additionally, the safety profile of the higher formulation was comparable with the lower arms, with 88.9% of all adverse events reported as mild. No serious adverse events were observed.

Reference:

Jeuveau: How it works. https://jeuveau.evolus.com/how-it-works. Accessed Nov. 11, 2023.